Company / Capital Expenditures
Relay Therapeutics, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$410.0K
FY2025
5-year range
$410.0K / $8.0M
FY2021-FY2025
Trend
-79.7%
vs FY2024
Sector context
#143 of 194
Health Care
What the data says
At $410,000, Relay Therapeutics, Inc.'s capital expenditures ranks #143 of 194 in the Health Care sector. Declined from $4M to $410,000 over the past 2 years.
Based on SEC 10-K filings.
$410,000 in FY2025 with a 5-year CAGR of -44.8%.
Declined from $4M to $410,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -40.3%
- 5-Year CAGR
- -44.8%
- 10-Year CAGR
- -
Sector benchmark
#143 of 194 in Health CareTop 74% of 194This company $410.0K Sector average $117.5M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -44.8%, indicating a declining trend.
- In FY2025, capital expenditures decreased 79.7% year-over-year.
- Ranks #143 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $410.0K | -79.7% |
| FY2024 | $2.0M | -51.1% |
| FY2023 | $4.1M | +113.7% |
| FY2022 | $1.9M | -75.9% |
| FY2021 | $8.0M | +0.0% |
| FY2020 | $8.0M | +0.0% |
| FY2019 | $8.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026